- Home
- GENK vs XLO Comparison
GENK vs XLO Comparison
Compare GENK & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- XLO
- Stock Information
- Founded
- GENK 2011
- XLO 2016
- Country
- GENK United States
- XLO United States
- Employees
- GENK N/A
- XLO N/A
- Industry
- GENK Restaurants
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- XLO Health Care
- Exchange
- GENK Nasdaq
- XLO Nasdaq
- Market Cap
- GENK 36.5M
- XLO 37.9M
- IPO Year
- GENK 2023
- XLO 2021
- Fundamental
- Price
- GENK $5.51
- XLO $0.93
- Analyst Decision
- GENK Strong Buy
- XLO Buy
- Analyst Count
- GENK 3
- XLO 1
- Target Price
- GENK $13.17
- XLO $4.00
- AVG Volume (30 Days)
- GENK 63.0K
- XLO 10.5M
- Earning Date
- GENK 03-05-2025
- XLO 03-31-2025
- Dividend Yield
- GENK N/A
- XLO N/A
- EPS Growth
- GENK 483.78
- XLO N/A
- EPS
- GENK 0.17
- XLO N/A
- Revenue
- GENK $198,834,000.00
- XLO $4,620,000.00
- Revenue This Year
- GENK $14.66
- XLO N/A
- Revenue Next Year
- GENK $21.47
- XLO $558.79
- P/E Ratio
- GENK $33.95
- XLO N/A
- Revenue Growth
- GENK 12.50
- XLO N/A
- 52 Week Low
- GENK $5.26
- XLO $0.55
- 52 Week High
- GENK $14.46
- XLO $1.93
- Technical
- Relative Strength Index (RSI)
- GENK 31.30
- XLO 48.99
- Support Level
- GENK $5.26
- XLO $0.97
- Resistance Level
- GENK $5.73
- XLO $1.22
- Average True Range (ATR)
- GENK 0.35
- XLO 0.14
- MACD
- GENK 0.01
- XLO 0.03
- Stochastic Oscillator
- GENK 18.52
- XLO 28.04
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).